Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping

Gordon F. Schwartz; Harry Bartelink; Harold J. Burstein; Blake Cady; Luigi Cataliotti; Ian Fentiman; Roland Holland; Kevin S. Hughes; Shahla Masood; Beryl McCormick; Juan A. Palazzo; Peter I. Pressman; Jorge Reis-Filho; Lajos Pusztai; Emiel J. T. Rutgers; Andrew D. Seidman; Lawrence J. Solin; Joseph A. Sparano

doi:10.1111/j.1524-4741.2012.01264.x

Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping

Gordon F. Schwartz^*, Harry Bartelink, Harold J. Burstein, Blake Cady, Luigi Cataliotti, Ian Fentiman, Roland Holland, Kevin S. Hughes, Shahla Masood, Beryl McCormick, Juan A. Palazzo, Peter I. Pressman, Jorge Reis-Filho, Lajos Pusztai, Emiel J. T. Rutgers, Andrew D. Seidman, Lawrence J. Solin, Joseph A. Sparano

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

Original language	English
Pages (from-to)	303-311
Number of pages	9
Journal	The Breast Journal
Volume	18
Issue number	4
DOIs	https://doi.org/10.1111/j.1524-4741.2012.01264.x
Publication status	Published - Jul 2012

Keywords

adjuvant therapy
breast carcinoma
estrogen receptors
gene analysis
Her-2-neu
progesterone receptors
Ki-67
CANCER
EXPRESSION
RECURRENCE
RISK
CHEMOTHERAPY
PREDICTION
PROGNOSIS
TAMOXIFEN
SUBTYPES
MARKERS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1524-4741.2012.01264.x

Cite this

Schwartz, G. F., Bartelink, H., Burstein, H. J., Cady, B., Cataliotti, L., Fentiman, I., Holland, R., Hughes, K. S., Masood, S., McCormick, B., Palazzo, J. A., Pressman, P. I., Reis-Filho, J., Pusztai, L., Rutgers, E. J. T., Seidman, A. D., Solin, L. J., & Sparano, J. A. (2012). Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. The Breast Journal, 18(4), 303-311. https://doi.org/10.1111/j.1524-4741.2012.01264.x

@article{b4910ebe3be74b78b60e984387144c14,

title = "Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping",

abstract = "A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.",

keywords = "adjuvant therapy, breast carcinoma, estrogen receptors, gene analysis, Her-2-neu, progesterone receptors, Ki-67, CANCER, EXPRESSION, RECURRENCE, RISK, CHEMOTHERAPY, PREDICTION, PROGNOSIS, TAMOXIFEN, SUBTYPES, MARKERS",

author = "Schwartz, {Gordon F.} and Harry Bartelink and Burstein, {Harold J.} and Blake Cady and Luigi Cataliotti and Ian Fentiman and Roland Holland and Hughes, {Kevin S.} and Shahla Masood and Beryl McCormick and Palazzo, {Juan A.} and Pressman, {Peter I.} and Jorge Reis-Filho and Lajos Pusztai and Rutgers, {Emiel J. T.} and Seidman, {Andrew D.} and Solin, {Lawrence J.} and Sparano, {Joseph A.}",

year = "2012",

month = jul,

doi = "10.1111/j.1524-4741.2012.01264.x",

language = "English",

volume = "18",

pages = "303--311",

journal = "The Breast Journal",

issn = "1075-122X",

publisher = "Wiley-Blackwell",

number = "4",

}

Schwartz, GF, Bartelink, H, Burstein, HJ, Cady, B, Cataliotti, L, Fentiman, I, Holland, R, Hughes, KS, Masood, S, McCormick, B, Palazzo, JA, Pressman, PI, Reis-Filho, J, Pusztai, L, Rutgers, EJT, Seidman, AD, Solin, LJ & Sparano, JA 2012, 'Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping', The Breast Journal, vol. 18, no. 4, pp. 303-311. https://doi.org/10.1111/j.1524-4741.2012.01264.x

TY - JOUR

T1 - Adjuvant Therapy in Stage I Carcinoma of the Breast

T2 - The Influence of Multigene Analyses and Molecular Phenotyping

AU - Schwartz, Gordon F.

AU - Bartelink, Harry

AU - Burstein, Harold J.

AU - Cady, Blake

AU - Cataliotti, Luigi

AU - Fentiman, Ian

AU - Holland, Roland

AU - Hughes, Kevin S.

AU - Masood, Shahla

AU - McCormick, Beryl

AU - Palazzo, Juan A.

AU - Pressman, Peter I.

AU - Reis-Filho, Jorge

AU - Pusztai, Lajos

AU - Rutgers, Emiel J. T.

AU - Seidman, Andrew D.

AU - Solin, Lawrence J.

AU - Sparano, Joseph A.

PY - 2012/7

Y1 - 2012/7

N2 - A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

AB - A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.

KW - adjuvant therapy

KW - breast carcinoma

KW - estrogen receptors

KW - gene analysis

KW - Her-2-neu

KW - progesterone receptors

KW - Ki-67

KW - CANCER

KW - EXPRESSION

KW - RECURRENCE

KW - RISK

KW - CHEMOTHERAPY

KW - PREDICTION

KW - PROGNOSIS

KW - TAMOXIFEN

KW - SUBTYPES

KW - MARKERS

U2 - 10.1111/j.1524-4741.2012.01264.x

DO - 10.1111/j.1524-4741.2012.01264.x

M3 - Article

SN - 1075-122X

VL - 18

SP - 303

EP - 311

JO - The Breast Journal

JF - The Breast Journal

IS - 4

ER -

Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this